S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
Log in
NASDAQ:ISRG

Intuitive Surgical Competitors

$752.01
+7.93 (+1.07 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$735.64
Now: $752.01
$754.65
50-Day Range
$744.08
MA: $790.50
$818.75
52-Week Range
$360.50
Now: $752.01
$826.81
Volume1.10 million shs
Average Volume710,193 shs
Market Capitalization$88.40 billion
P/E Ratio85.65
Dividend YieldN/A
Beta0.98

Competitors

Intuitive Surgical (NASDAQ:ISRG) Vs. ABT, MDT, SYK, BDX, EW, and BSX

Should you be buying ISRG stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Intuitive Surgical, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), and Boston Scientific (BSX).

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and target prices for Abbott Laboratories and Intuitive Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories121302.75
Intuitive Surgical381002.33

Abbott Laboratories currently has a consensus price target of $115.6875, suggesting a potential upside of 0.84%. Intuitive Surgical has a consensus price target of $736.0588, suggesting a potential downside of 2.12%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, equities analysts plainly believe Abbott Laboratories is more favorable than Intuitive Surgical.

Risk and Volatility

Abbott Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Abbott Laboratories and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Intuitive Surgical24.45%12.08%10.44%

Insider and Institutional Ownership

72.6% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Abbott Laboratories and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.37$3.69 billion$3.2435.41
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58

Abbott Laboratories has higher revenue and earnings than Intuitive Surgical. Abbott Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Intuitive Surgical and Medtronic, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical381002.33
Medtronic032012.92

Intuitive Surgical currently has a consensus price target of $736.0588, suggesting a potential downside of 2.12%. Medtronic has a consensus price target of $122.2963, suggesting a potential upside of 4.62%. Given Medtronic's stronger consensus rating and higher probable upside, analysts plainly believe Medtronic is more favorable than Intuitive Surgical.

Profitability

This table compares Intuitive Surgical and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Medtronic12.69%9.71%5.30%

Risk and Volatility

Intuitive Surgical has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Institutional & Insider Ownership

86.5% of Intuitive Surgical shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by insiders. Comparatively, 0.5% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Intuitive Surgical and Medtronic's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58
Medtronic$28.91 billion5.44$4.79 billion$4.5925.47

Medtronic has higher revenue and earnings than Intuitive Surgical. Medtronic is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats Medtronic on 9 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Profitability

This table compares Stryker and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker12.35%20.94%8.77%
Intuitive Surgical24.45%12.08%10.44%

Analyst Recommendations

This is a summary of current recommendations for Stryker and Intuitive Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker271412.58
Intuitive Surgical381002.33

Stryker currently has a consensus price target of $227.4783, indicating a potential downside of 5.04%. Intuitive Surgical has a consensus price target of $736.0588, indicating a potential downside of 2.12%. Given Intuitive Surgical's higher possible upside, analysts clearly believe Intuitive Surgical is more favorable than Stryker.

Insider and Institutional Ownership

71.5% of Stryker shares are owned by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Stryker and Intuitive Surgical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion6.05$2.08 billion$8.2629.00
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58

Stryker has higher revenue and earnings than Intuitive Surgical. Stryker is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Stryker has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Summary

Intuitive Surgical beats Stryker on 8 of the 15 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

83.2% of Becton, Dickinson and shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 0.8% of Becton, Dickinson and shares are held by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Becton, Dickinson and and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
Intuitive Surgical24.45%12.08%10.44%

Risk and Volatility

Becton, Dickinson and has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Becton, Dickinson and and Intuitive Surgical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07702.50
Intuitive Surgical381002.33

Becton, Dickinson and currently has a consensus price target of $279.6667, indicating a potential upside of 7.46%. Intuitive Surgical has a consensus price target of $736.0588, indicating a potential downside of 2.12%. Given Becton, Dickinson and's stronger consensus rating and higher probable upside, analysts plainly believe Becton, Dickinson and is more favorable than Intuitive Surgical.

Valuation & Earnings

This table compares Becton, Dickinson and and Intuitive Surgical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion4.42$874 million$10.2025.51
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58

Intuitive Surgical has lower revenue, but higher earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats Becton, Dickinson and on 8 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

80.9% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Edwards Lifesciences and Intuitive Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences271202.48
Intuitive Surgical381002.33

Edwards Lifesciences currently has a consensus price target of $90.8704, suggesting a potential upside of 5.80%. Intuitive Surgical has a consensus price target of $736.0588, suggesting a potential downside of 2.12%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Edwards Lifesciences is more favorable than Intuitive Surgical.

Profitability

This table compares Edwards Lifesciences and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Intuitive Surgical24.45%12.08%10.44%

Earnings and Valuation

This table compares Edwards Lifesciences and Intuitive Surgical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.31$1.05 billion$1.8646.18
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58

Intuitive Surgical has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats Edwards Lifesciences on 9 of the 14 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Earnings & Valuation

This table compares Intuitive Surgical and Boston Scientific's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58
Boston Scientific$10.74 billion4.91$4.70 billion$1.5823.28

Boston Scientific has higher revenue and earnings than Intuitive Surgical. Boston Scientific is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Intuitive Surgical and Boston Scientific, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical381002.33
Boston Scientific031722.95

Intuitive Surgical presently has a consensus price target of $736.0588, suggesting a potential downside of 2.12%. Boston Scientific has a consensus price target of $43.0870, suggesting a potential upside of 17.15%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than Intuitive Surgical.

Institutional and Insider Ownership

86.5% of Intuitive Surgical shares are held by institutional investors. Comparatively, 90.7% of Boston Scientific shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by insiders. Comparatively, 0.7% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Intuitive Surgical and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Boston Scientific36.59%11.77%5.57%

Volatility and Risk

Intuitive Surgical has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Summary

Boston Scientific beats Intuitive Surgical on 8 of the 15 factors compared between the two stocks.


Intuitive Surgical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$114.72+1.6%$203.33 billion$31.90 billion60.70Upcoming Earnings
Medtronic logo
MDT
Medtronic
2.7$116.90+0.3%$157.35 billion$28.91 billion44.62
Stryker logo
SYK
Stryker
2.0$239.55+0.2%$90.02 billion$14.88 billion51.96Upcoming Earnings
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$260.24+0.6%$75.69 billion$17.12 billion95.33Dividend Announcement
News Coverage
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$85.89+0.4%$53.53 billion$4.35 billion68.71Upcoming Earnings
Boston Scientific logo
BSX
Boston Scientific
2.2$36.78+0.7%$52.67 billion$10.74 billion14.09
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$489.21+0.7%$41.73 billion$2.41 billion85.23Upcoming Earnings
Baxter International logo
BAX
Baxter International
2.3$80.10+0.7%$40.92 billion$11.36 billion45.51
DexCom logo
DXCM
DexCom
1.9$376.39+1.7%$36.14 billion$1.48 billion155.53Insider Selling
ResMed logo
RMD
ResMed
1.4$221.68+2.8%$32.12 billion$2.96 billion47.57Upcoming Earnings
Hologic logo
HOLX
Hologic
1.9$76.34+0.8%$19.62 billion$3.78 billion18.18Upcoming Earnings
Insulet logo
PODD
Insulet
1.3$288.91+0.5%$19.05 billion$738.20 million656.63
Teleflex logo
TFX
Teleflex
2.0$382.14+1.1%$17.80 billion$2.60 billion49.18
STERIS logo
STE
STERIS
2.1$190.41+0.9%$16.25 billion$3.03 billion38.62Upcoming Earnings
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$175.33+0.1%$16.02 billion$3.17 billion59.84
Abiomed logo
ABMD
Abiomed
1.5$348.32+0.1%$15.74 billion$840.88 million76.55Upcoming Earnings
Masimo logo
MASI
Masimo
1.4$257.09+2.6%$14.15 billion$937.84 million66.78
Hill-Rom logo
HRC
Hill-Rom
2.0$101.16+1.7%$6.71 billion$2.88 billion30.47
Globus Medical logo
GMED
Globus Medical
1.4$64.44+1.4%$6.36 billion$785.37 million70.04
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.36+0.1%$5.85 billion$1.52 billion103.52
NuVasive logo
NUVA
NuVasive
1.5$56.80+0.2%$2.91 billion$1.17 billion-258.18
AtriCure logo
ATRC
AtriCure
1.3$58.30+1.3%$2.62 billion$230.81 million-50.70
Integer logo
ITGR
Integer
2.3$78.15+1.2%$2.57 billion$1.26 billion35.52
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$46.51+0.3%$1.87 billion$236.54 million-70.47
Alphatec logo
ATEC
Alphatec
0.8$14.92+0.7%$1.17 billion$113.43 million-13.56
CryoLife logo
CRY
CryoLife
1.5$24.96+1.2%$969.87 million$276.22 million-65.68
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$44.94+2.2%$868.77 million$459.95 million37.45
AngioDynamics logo
ANGO
AngioDynamics
1.6$18.55+1.9%$704.04 million$264.16 million-4.15
Surmodics logo
SRDX
Surmodics
1.5$46.33+1.0%$633.89 million$94.86 million579.13News Coverage
Accuray logo
ARAY
Accuray
2.2$5.08+0.6%$463.67 million$382.93 million36.29Upcoming Earnings
Invacare logo
IVC
Invacare
1.6$9.92+0.1%$341.43 million$927.96 million-8.06
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.46+2.7%$136.62 million$61.30 million-3.40
This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.